PARP-1 inhibitors can be utilized not only as a single agent for the treatment of BRCA1- or BRCA2-deficient cancers, but in combination with DNA-damaging therapeutics (radiation or chemotherapy) to improve their potencies by blocking DNA-repairing process. The gene discussed is BRCA1; the disease is cancer.